Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

The Estrogen Receptor Negative-Progesterone Receptor Positive Breast Carcinoma is a Biological Entity and not a Technical Artifact

  • Ng, Char Hong (Department of Surgery, Faculty of Medicine, University of Malaya) ;
  • Pathy, Nirmala Bhoo (Julius Center University of Malaya) ;
  • Taib, Nur Aishah (Department of Surgery, Faculty of Medicine, University of Malaya) ;
  • Mun, Kein Seong (Department of Pathology, Faculty of Medicine, University of Malaya) ;
  • Rhodes, Anthony (Faculty of Health and Life Sciences, University of the West of England) ;
  • Yip, Cheng Har (Department of Surgery, Faculty of Medicine, University of Malaya)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The ER-/PR+ breast tumor may be the result of a false ER negative result. The aim of this study was to investigate whether there is a difference in patient and tumor characteristics of the ER-/PR+ phenotype in an Asian setting. A total of 2629 breast cancer patients were categorized on the basis of their age, ethnicity, tumor hormonal receptor phenotype, grade and histological type. There were 1230 (46.8%) ER+/PR+, 306 (11.6%) ER+/PR-, 122 (4.6%) ER-/PR+ and 972 (37%) ER-/PR-. ER-/PR+ tumors were 2.5 times more likely to be younger than 50 years at diagnosis (OR: 2.52; 95% CI: 1.72-3.67). Compared to ER+/PR+ tumors, the ER-/PR+ phenotype was twice more likely to be associated with grade 3 tumors (OR:2.02; 95%CI: 1.00-4.10). In contrast, compared to ER-/PR- tumors, the ER-/PR+ phenotype was 90% less likely to be associated with a grade 3 tumor (OR: 0.12; 95%CI:0.05-0.26), and more likely to have invasive lobular than invasive ductal histology (OR: 3.66; 95%CI: 1.47-9.11). These results show that the ER-/PR+ phenotype occurs in a younger age group and is associated with intermediate histopathological characteristics compared to ER+/PR+ and ER-/PR- tumors. This may imply that it is a distinct entity and not a technical artifact.

Keywords

References

  1. Bhoo Pathy N, Yip CH, ONE AUTHOR, et al (2011). Breast cancer in a multi-ethnic Asian setting: Results from the Singapore-Malaysia hospital-based breast cancer registry. Breast.??
  2. Chow LW, Ho P (2000). Hormonal receptor determination of 1,052 Chinese breast cancers. J Surg Oncol, 75, 172-5. https://doi.org/10.1002/1096-9098(200011)75:3<172::AID-JSO4>3.0.CO;2-A
  3. De Maeyer L, Van Limbergen E, ONE AUTHOR, et al (2008). Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?" J Clin Oncol, 26, 335-6 https://doi.org/10.1200/JCO.2007.14.8411
  4. Dunnwald LK, Rossing MA, ONE AUTHOR, et al (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients." Breast Cancer Res, 9, 6-?. https://doi.org/10.1186/bcr1639
  5. Nadji M (2008). Quantitative immunohistochemistry of estrogen receptor in breast cancer: "much ado about nothing!". Appl Immunohistochem Mol Morphol, 16, 105-7. https://doi.org/10.1097/PAI.0b013e3181607323
  6. Nadji M, C Gomez-Fernandez, ONE AUTHOR, et al (2005)."Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers." Am J Clin Pathol, 123, 21-7. https://doi.org/10.1309/4WV79N2GHJ3X1841
  7. Rakha E A, El-Sayed ME, ONE AUTHOR, et al (2007). Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol, 25, 4772-8. https://doi.org/10.1200/JCO.2007.12.2747
  8. Rakha EA, Reis-Filho JS, ONE AUTHOR, et al (2010). Combinatorial biomarker expression in breast cancer. Breast Cancer Res, 120, 293-308. https://doi.org/10.1007/s10549-010-0746-x
  9. Rhodes, Jasani AB (2009). The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol, 62, 95-6.
  10. Rhodes, Jasani AB, ONE AUTHOR, et al (2000). Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol, 53, 688-96. https://doi.org/10.1136/jcp.53.9.688
  11. Yip CH (2009). Breast cancer in Asia. Methods Mol Biol, 471, 51-64. https://doi.org/10.1007/978-1-59745-416-2_3

Cited by

  1. Do Clinical Features and Survival of Single Hormone Receptor Positive Breast Cancers Differ from Double Hormone Receptor Positive Breast Cancers? vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7959
  2. Heterogeneity of Breast Cancer Clinical Characteristics and Outcome in US Black Women-Effect of Place of Birth vol.20, pp.5, 2014, https://doi.org/10.1111/tbj.12302
  3. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers vol.2014, pp.1687-8566, 2014, https://doi.org/10.1155/2014/469251
  4. Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia vol.31, pp.6, 2014, https://doi.org/10.1007/s12032-014-0977-5
  5. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer vol.10, pp.7, 2015, https://doi.org/10.1371/journal.pone.0132449
  6. Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities vol.34, pp.4, 2015, https://doi.org/10.1007/s10555-014-9543-z
  7. Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact? pp.1532-2807, 2017, https://doi.org/10.1007/s12253-017-0304-5
  8. Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer vol.73, pp.4, 2018, https://doi.org/10.1111/his.13523